PTO/SB/64 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
D a collection of information unless it displays a valid OMB control authority.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

PETITION FOR REVIVAL OF AN APPLICATION FOR ABANDONED UNINTENTIONALLY UNDER 37 CFR 1	PATENT	Docket Number (Optional) TOMK0004	
First named inventor: Mohammad Reza MEHRABI			
Application No.:	Art Unit:		
Filed: January 10, 2005	Examiner:		
Title: USE OF ALPROSTADIL (PROSTAGLANDIN E1) FOR PRODUCING A MEDICAMENT FOR ANGIONEOGENESIS			
Attention: Office of Petitions  Mail Stop Petition  Commissioner for Patents P.O. Box 1450  Alexandria, VA 22313-1450  FAX (703) 872-9306			
NOTE: If information or assistance is needed in completing this form, please contact Petitions Information at (703) 305-9282.			
The above-identified application became abandoned for failure to file a timely and proper reply to a notice or action by the United States Patent and Trademark Office. The date of abandonment is the day after the expiration date of the period set for reply in the office notice or action plus an extensions of time actually obtained.  APPLICANT HEREBY PETITIONS FOR REVIVAL OF THIS APPLICATION			
NOTE: A grantable petition requires the following items:  (1) Petition fee; (2) Reply and/or issue fee; (3) Terminal disclaimer with disclaimer fee - required for all utility and plant applications filed before June 8, 1995; and for all design applications; and  (4) Statement that the entire delay was unintentional.			
1.Petition fee Small entity-fee \$ (37 CFR 1.17(m)). Applicant claims small entity status. See 37 CFR 1.27.			
X Other than small entity – fee \$ 1,500.00 (37 CFR 1.1	7(m))		
Reply and/or fee     A. The reply and/or fee to the above-noted Office action the form of has been filed previously on		ify type of reply):	
is enclosed herewith.  B. The issue fee and publication fee (if applicable) of \$			

This collection of information is required by 37 CFR 1.137(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Petition, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

01/14/2005 GFREY1 00000149 lf you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/64 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

3. Terminal disclaimer with disclaimer fee			
X Since this utility/plant application was filed on or after June 8, 1995, no terminal disclaimer is required.			
A terminal disclaimer (and disclaimer fee (37 CFR 1.20(d)) of \$ for a small entity or \$ for other than a small entity) disclaiming the required period of time is enclosed herewith (see PTO/SB/63).			
4. STATEMENT: The entire delay in filing the refiling of a grantable petition under 37 CFR 1. Trademark Office may require additional information of the control of the con	equired reply from the due date for the required reply until the 137(b) was unintentional. [NOTE: The United States Patent and rmation if there is a question as to whether either the under 37 CFR 1.137(b) was unintentional (MPEP 711.03(c),		
	ay become public. Credit card information should not be eard information and authorization on PTO-2038.		
	Poste Pate		
DR. MOHAMAD			
Typed or printed na	<u>··V·i</u>		
A- 1230 VIENNA HOSE	ETIGGASSE &		
Address	Telephone Number		
AUSTRIA			
Address Enclosures: X Fee Payment			
Reply			
Terminal Disclaimer Form			
Additional sheets containing	statements establishing unintentional delay		
Other:			
}			
CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR 1.8(a)]			
postage as first class mail in an e Patents, P. O. Box 1450, Alexand	Postal Service on the date shown below with sufficient envelope addressed to: Mail Stop Petition, Commissioner for dria, VA 22313-1450.		
Transmitted by facsimile on the d Office as (703) 872-9306.	ate shown below to the United States Patent and Trademark		
Date	Signature		
	Typed or printed name of person signing certificate		

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.

Confirmation No.

Applicant:

Mohammad Reza

**MEHRABI** 

Filed:

TC/A.U.

Examiner:

Docket No.

**TOMK0004** 

Customer No.

25235

Communation No.

Title: USE OF ALPROSTADIL

(PROSTAGLANDIN E1) FOR PRODUCING A MEDICAMENT FOR ANGIONEOGENESIS

## **DECLARATION OF MOHAMMAD REZA MEHRABI**

Commissioner for Patents Alexandria, VA 22313-1450

Sir:

## I, Mohammed Reza MEHRABI, do declare as follows:

- I am the applicant/sole inventor of PCT/AT00/00252 filed September 21, 2000, which claims priority of Austria Patent application No. A 1635/99 filed September 29, 1999, from which the present application is a U.S. national filing.
- 2. It just came to my attention that March 29, 2002 was the deadline for filing a U.S. patent application based upon PCT/AT00/00252 and that a U.S. national filing was not undertaken by that date.
- 3. Having just learned a national filing was not completed in the U.S. for PCT/AT00/00252 by March 29, 2002, I promptly authorized European patent counsel to engage U.S. patent counsel to undertake a U.S. national filing as promptly as possible, and do

hereby state that the failure to file such a U.S. patent application was at all times on and after March 29, 2002, unintentional.

4. I hereby declare that all statements made herein of my own knowledge are true and all statements made on information and belief are believed to be true. I further declare I understand that willful false statements and the like made herein are punishable by fine or imprisonment, or both (18 U.S.C. § 1001) and may jeopardize the validity of the above-referenced application or any patent issuing thereon.

Respectfully submitted,

01/05/2005

December \_\_\_, 2004

Mohammad Reza MEHRABI